Showing 41 - 60 results of 131 for search '"cytochrome P450"', query time: 0.04s Refine Results
  1. 41

    A Computational Approach towards the Development of Newer Anticancer Agents by Javed I. Sheikh, H. D. Juneja, V. N. Ingle

    Published 2010-01-01
    “…In silico molecular docking analyses of the novel 1-(2', 4'-dihydroxy-5'-chlorophenyl)-3-aryl-propane-1, 3-diones were performed in the active sites of enzyme cytochrome P450 reductase to obtain new anticancer agents computationally. 1-(2', 4'-dihydroxy-5'-chlorophenyl)-3-(4"-methoxy-phenyl)-propane-1, 3-dione (3f) was found to have maximum affinity for the active sites of enzyme.…”
    Get full text
    Article
  2. 42

    Hepatic changes during a carrageenan induced granuloma in rats by J. Muntané, Y. Fernandez, S. Mitjavila, M. T. Mitjavila

    Published 1993-01-01
    “…The continuous increase in hepatic cAMP observed during acute and chronic phases could be related to adenylate cyclase stimulation by mediators, and could be an initial step in the hepatocyte adaptation leading to the increased level of hepatic caeruloplasmin, to the reduction of cytochrome P-450 level and to the modifications of Ca2+ sequestration by microsomes.…”
    Get full text
    Article
  3. 43

    Treatment of Severe Acetaminophen–Induced Hepatocellular Injury with Prostaglandin E: Two Case Reports by Marina Khatchatourian, Hillar Vellend

    Published 1995-01-01
    “…Acetaminophen hepatotoxicity is mediated by a toxic reactive metabolite formed from the parent compound by the cytochrome P450 mixed-function oxidase system of the hepatocyte. …”
    Get full text
    Article
  4. 44

    Modulation of Metabolic Detoxification Pathways Using Foods and Food-Derived Components: A Scientific Review with Clinical Application by Romilly E. Hodges, Deanna M. Minich

    Published 2015-01-01
    “…Various clinical and in vivo studies have been undertaken to evaluate the effects of foods and food-derived components on the activity of detoxification pathways, including phase I cytochrome P450 enzymes, phase II conjugation enzymes, Nrf2 signaling, and metallothionein. …”
    Get full text
    Article
  5. 45

    The gut–kidney axis is regulated by astragaloside IV to inhibit cyclosporine A-induced nephrotoxicity by Cong Han, Ran-ran Gao, Le Zhou, Wei Li

    Published 2025-01-01
    “…The six pathways related to energy metabolism driven by L. reuteri, including the citrate cycle, ascorbate and alderate metabolism, proximal tube bicarbonate metabolism, glycolysis/gluconeogenesis, ferroptosis, drug metabolism–cytochrome P450, are important mechanisms.…”
    Get full text
    Article
  6. 46

    Metabolic resistance to pyrethroids with possible involvement of non-coding ribonucleic acids in Anopheles funestus, the major malaria vector in western Kenya by Isaiah Debrah, Daibin Zhong, Maxwell G. Machani, Godfrey Nattoh, Kevin O. Ochwedo, Collins M. Morang’a, Ming-Chieh Lee, Linda E. Amoah, Andrew K. Githeko, Yaw A. Afrane, Guiyun Yan

    Published 2025-01-01
    “…A synergist assay using piperonyl butoxide (PBO) (4%) was conducted to determine cytochrome P450s’ role in pyrethroid resistance. RNA-seq was conducted on a combined pool of specimens that were resistant and unexposed, and the results were compared with those of the FANG susceptible reference strain. …”
    Get full text
    Article
  7. 47

    Sorafenib-Induced Liver Failure: A Case Report and Review of the Literature by Anneleen Van Hootegem, Chris Verslype, Werner Van Steenbergen

    Published 2011-01-01
    “…We hypothesize that an underlying cytochrome P450 dysfunction with the presence of reactive drug metabolites might lead to this potentially fatal Sorafenib-induced severe liver dysfunction.…”
    Get full text
    Article
  8. 48

    How to Make the Right Choice of Proton Pump Inhibitor for Patients with Gastroesophageal Reflux Disease? by Yu. V. Evsyutina

    Published 2023-06-01
    “…Pantoprazole is distinguished from other PPIs by its persistent high bioavailability, long-term antisecretory effect, and very low affinity for cytochrome P450.…”
    Get full text
    Article
  9. 49

    Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole by O. D. Lopina, B. K. Nurgalieva, T. L. Lapina

    Published 2021-12-01
    “…A lower rabeprazole metabolic dependence on cytochrome P-450 enzyme system renders its antisecretory effect predictable and reduces the risk of interactions with other drugs metabolised through this system. …”
    Get full text
    Article
  10. 50

    Pathway and molecular mechanisms for malachite green biodegradation in Exiguobacterium sp. MG2. by Ji'ai Wang, Feng Gao, Zhongzhong Liu, Min Qiao, Xuemei Niu, Ke-Qin Zhang, Xiaowei Huang

    Published 2012-01-01
    “…Furthermore, our molecular biology experiments suggested that both triphenylmethane reductase gene tmr and cytochrome P450 participated in MG degradation, consistent with their roles in the proposed pathway. …”
    Get full text
    Article
  11. 51

    Severe Rhabdomyolysis Associated with Simvastatin and Role of Ciprofloxacin and Amlodipine Coadministration by Nicolas De Schryver, Xavier Wittebole, Peter Van den Bergh, Vincent Haufroid, Eric Goffin, Philippe Hantson

    Published 2015-01-01
    “…This is particularly true for drugs that are extensively metabolized by cytochrome P450 (CYP)3A4. We describe a particularly severe case of rhabdomyolysis after the introduction of ciprofloxacin, a weak CYP3A4 inhibitor, in a patient who previously tolerated the simvastatin-amlodipine combination.…”
    Get full text
    Article
  12. 52

    Uncover the Underlying Mechanism of Drug-Induced Myopathy by Using Systems Biology Approaches by Dong Li, Aixin Li, Hairui Zhou, Xi Wang, Peng Li, Sheng Bi, Yang Teng

    Published 2017-01-01
    “…Specifically, the similarity of DIM drugs is more significant than random chance, which shows that the chemical structure could distinguish the DIM-positive drugs from negatives. The cytochrome P450 (CYP) was identified to be shared by DIM drugs, which indicated the important role of metabolism in DIM. …”
    Get full text
    Article
  13. 53

    Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes by Mark Johnson, Craig Richard, Renee Bogdan, Robert Kidd

    Published 2014-01-01
    “…Genetic factors most correlated with warfarin dose requirements are variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR). …”
    Get full text
    Article
  14. 54

    Cyclosporine and Herbal Supplement Interactions by D. Colombo, L. Lunardon, G. Bellia

    Published 2014-01-01
    “…Its bioavailability is affected by many other traditional drugs and herbal extracts. Cytochrome P-450 isoenzymes CYP3A4 and CYP3A5 and protein P-glycoprotein (P-gp) are involved in CyA bioavailability. …”
    Get full text
    Article
  15. 55

    International Normalized Ratio (INR) Increases amongst Two Patients Living with HIV on Warfarin after Being Switched from a Nevirapine to a Dolutegravir-Based Antiretroviral Regime... by Natalie Sang, Sonak Pastakia, Samuel Nyanje

    Published 2021-01-01
    “…Nevirapine is an enzyme inducer and increases the dosing requirements for cytochrome P450 enzyme substrates including warfarin. …”
    Get full text
    Article
  16. 56

    All-Trans Retinoic Acid-Induced Pseudotumor Cerebri during Induction Therapy for Acute Promyelocytic Leukemia: A Case Report and Literature Review by Dylan Holmes, Prakash Vishnu, Russell K. Dorer, David M. Aboulafia

    Published 2012-01-01
    “…Concomitant administration of medications such as triazole antifungals which influence the cytochrome P-450 system can exacerbate this potential complication of ATRA. …”
    Get full text
    Article
  17. 57

    Anti-Inflammatory Effects of Epoxyeicosatrienoic Acids by Scott J. Thomson, Ara Askari, David Bishop-Bailey

    Published 2012-01-01
    “…Epoxyeicosatrienoic acids (EETs) are generated by the activity of both selective and also more general cytochrome p450 (CYP) enzymes on arachidonic acid and inactivated largely by soluble epoxide hydrolase (sEH), which converts them to their corresponding dihydroxyeicosatrienoic acids (DHETs). …”
    Get full text
    Article
  18. 58

    Pharmacogenetics of Oral Antidiabetic Drugs by Matthijs L. Becker, Ewan R. Pearson, Ivan Tkáč

    Published 2013-01-01
    “…CYP2C9 encodes sulfonylurea metabolizing cytochrome P450 isoenzyme 2C9, ABCC8 and KCNJ11 genes encode proteins constituting ATP-sensitive K+ channel which is a therapeutic target for sulfonylureas, and TCF7L2 is a gene with the strongest association with type 2 diabetes. …”
    Get full text
    Article
  19. 59

    Cyclophosphamide Pharmacogenomic Variation in Cancer Treatment and Its Effect on Bioactivation and Pharmacokinetics by Ibrahim El-Serafi, Sinclair Steele

    Published 2024-01-01
    “…Cyclophosphamide (Cy) is a prodrug that is mainly bioactivated by cytochrome P450 (CYP) 2B6 enzyme. Several other enzymes are also involved in its bioactivation and affect its kinetics. …”
    Get full text
    Article
  20. 60

    Western Diet Decreases Hepatic Drug Metabolism in Male LDLr−/−ApoB100/100 Mice by Markus Koponen, Jaana Rysä, Anna-Kaisa Ruotsalainen, Olli Kärkkäinen, Risto O. Juvonen

    Published 2023-01-01
    “…In this study, male LDLr−/−ApoB100/100 mice were fed with Western diet (WD) or a standard diet for five months to reveal the effects on drug metabolism such as cytochrome P450 (CYP) oxidation and conjugation activities in the liver. …”
    Get full text
    Article